Correction to Novartis Eye-Disease Drug Article on Tuesday
October 09 2019 - 1:38PM
Dow Jones News
Beovu showed it was non-inferior in terms of improvements in
visual acuity for patients compared with rival treatment
aflibercept. "Novartis Sees Blockbuster Potential in Eye-Disease
Drug -- Update," on Oct. 8 at GMT 1216, misstated that Beovu
achieved superior visual improvements compared with aflibercept in
the fifth paragraph. The error also appeared in an earlier version
of the story, "Novartis: US FDA Approves Eye-Disease Treatment
Beovu," at 0535 GMT the same day.
(END) Dow Jones Newswires
October 09, 2019 13:23 ET (17:23 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
